Ways2Capital Reviews : Dr. Reddy's Launches Amgen’s Repatha In India

Dr. Reddy's Laboratories has announced that it has launched Repatha 140 mg/ml in India. According to the company, this is the only PCSK9 Inhibitor available in India, approved by the Drug Controller General India (DCGI).

Repatha (evolocumab) is a patented product of Amgen global. It is a monoclonal antibody targeting PCSK9. It is indicated in the treatment of adult patients with elevated amounts of cholesterol or lipids in the blood. The drug was first approved by USFDA in 2015. Dr. Reddy's will distribute Repatha in India while it will be manufactured by Amgen.

In the US, the drug has achieved sales of $225mn in CY17, while global sales (including US) were $319mn.

Repatha is used either alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

Company has said that Repatha is a significant addition to Dr. Reddy's Cardiovascular portfolio, and it provides a unique treatment option to patients in India.

In the US, company is currently doing a recall of Atorvastatin Calcium, has received restraining order from the US court to stop selling gSuboxone and Dr. Reddy’s Laboratories (DRL) also lost a patent infringement case with Eli Lilly.
For Quick Trial – 8962000225 ✔ 
or mail us here: info@ways2capital.com 
or visit http://www.ways2capital.com 
✆ - 0731-6626191 | Toll Free - 1800-3010-2007
Give a Missed Call for Free Trial - 09699997717
Share on Google Plus Share on Pinterest

About Bhoomi Desai